HEK293/Human Glucagon Stable Cell
Item | Cat# | Price |
Stable Cell Line | SNB-G-0105A | $19,800 |
Compound Testing Services | CT-001 | $1,850 per 384w plate (Up To 16 cpds Dose) |
Product Description
The glucagon receptor (GCGR) is a class B G protein-coupled receptor primarily located on liver cells (hepatocytes), with additional presence in the kidneys, adipose tissue, and parts of the brain. Its core function is to bind and respond to the hormone glucagon by activating the Gs protein-cAMP-PKA signaling pathway, potently stimulating hepatic glycogenolysis and gluconeogenesis to raise blood glucose levels in response to fasting or hypoglycemia. It serves as a key regulator of systemic glucose homeostasis, counterbalancing the glucose-lowering action of insulin. This receptor is an important drug target for treating type 2 diabetes (via the development of receptor antagonists or dual-target agonists to modulate glucose) and the rare condition glucagonoma.
Screeningbio’s HEK293/Human Glucagon cell line overexpress GCGR and is designed to detect increases in intracellular cAMP levels in response to agonist stimulation of the receptor. Cisbio HTRF cAMP kit can be used to detect the signal.
Product Specifications
Target Type | GPCR |
Species | Human |
HGNC Symbol | GCGR |
Accession Number | NM_000160 |
Parental Line | HEK293 |
Lot# | See Vial |
Storage | Liquid Nitrogen |
Data
Target Background
The glucagon receptor (GCGR) is a class B G protein-coupled receptor primarily located on liver cells (hepatocytes), with additional presence in the kidneys, adipose tissue, and parts of the brain.
Its core function is to bind and respond to the hormone glucagon by activating the Gs protein-cAMP-PKA signaling pathway, potently stimulating hepatic glycogenolysis and gluconeogenesis to raise blood glucose levels in response to fasting or hypoglycemia.
It serves as a key regulator of systemic glucose homeostasis, counterbalancing the glucose-lowering action of insulin. This receptor is an important drug target for treating type 2 diabetes (via the development of receptor antagonists or dual-target agonists to modulate glucose) and the rare condition glucagonoma.